GlassScriptPhysician profile
Kamal Eldin E Ahmed
NPI 1952352411
$5,910.11
in general payments reported to CMS, 2019-2025
22 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $3,065 · 2021: $331 · 2022: $190 · 2023: $435 · 2024: $415 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049 · Education: $73.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.90 |
| Education | $73.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,229.24 | 2019-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $438.26 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Travere Therapeutics, INC. | $359.05 | 2022-2025 | Filspari |
| Glaxosmithkline, LLC. | $222.19 | 2021 | |
| Akebia Therapeutics INC | $212.09 | 2019-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $189.09 | 2023-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $139.51 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $130.87 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $130.82 | 2019-2025 | Voyxact |
| Novartis Pharmaceuticals Corporation | $121.46 | 2023-2025 | |
| Amgen INC. | $111.90 | 2019-2025 | Tavneos |
| Outset Medical INC | $100.82 | 2024 | |
| Opko Pharmaceuticals, LLC | $96.57 | 2020-2024 | Rayaldee |
| Vifor Pharma, INC. | $79.54 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $69.97 | 2025 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $62.17 | 2020 | |
| Amicus Therapeutics, INC. | $56.89 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $50.14 | 2020-2021 | |
| Kyowa Kirin, INC. | $50.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.68 | 2025 | Jardiance |
| Genzyme Corporation | $21.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Eldin Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.